COTA, Panalgo collaborate to enhance AI & RWD-enabled cancer care

AI test is equivalent to Oncotype DX at predicting breast cancer recurrence, study shows

COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.

December 13, 2024

Vol.50 No.46

In Brief

Siemens Healthineers, Ohio State Wexner Medical Center form 10-year, $105M partnership

Siemens Healthineers and The Ohio State Wexner Medical Center have expanded their existing strategic relationship to form a 10-year, $105 million value partnership to foster breakthroughs in clinical care, in addition to their longstanding research collaboration.

December 06, 2024

Vol.50 No.45

Clinical Roundup

RWE and phase I data support the role of Orserdu for ER+, HER2- advanced or metastatic breast cancer

The Menarini Group and Stemline Therapeutics will present new and expanded data on Orserdu at the upcoming 2024 San Antonio Breast Cancer Symposium, held from Dec. 10-13. The company will bring real-world progression-free survival results of Orserdu in adult patients with ER+/HER2-, advanced or metastatic breast cancer. Additionally, the company will present updated efficacy results of elacestrant plus abemaciclib, along with a pooled safety analysis from phase Ib/2 of both the ELECTRA and ELEVATE trials.

December 06, 2024

Vol.50 No.45

Clinical Roundup

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.

December 06, 2024

Vol.50 No.45

Drugs & Targets

ConcertAI and NeoGenomics announce AI software-as-a-service solution for hematology clinical research

ConcertAI announced a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization.

December 06, 2024

Vol.50 No.45

In Brief

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

The U.S. Department of Energy’s Argonne National Laboratory will use its world-leading capabilities in artificial intelligence and high-performance computing to research novel ways to fight cancer and advance vaccine discovery.

November 22, 2024

Vol.50 No.44

COTA, Panalgo collaborate to enhance AI & RWD-enabled cancer care

YOU MAY BE INTERESTED IN

AI test is equivalent to Oncotype DX at predicting breast cancer recurrence, study shows

Siemens Healthineers, Ohio State Wexner Medical Center form 10-year, $105M partnership

RWE and phase I data support the role of Orserdu for ER+, HER2- advanced or metastatic breast cancer

Cedars-Sinai to develop AI tool that predicts pancreatic cancer risk in Black patients

ConcertAI and NeoGenomics announce AI software-as-a-service solution for hematology clinical research

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

Renew today!

Subscriber content

Never miss an issue!

Login